Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease

Abstract Introduction Trials in Alzheimer's disease (AD) now include participants at the earliest stages to prevent further decline. However, the lack of tools sensitive to subtle functional changes in early‐stage AD hinders the development of new therapies as it is difficult to prove their cli...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah‐Christine Villeneuve, Marion Houot, Federica Cacciamani, Merike Verrijp, Bruno Dubois, Sietske Sikkes, Stéphane Epelbaum, MEMENTO study group and the INSIGHT‐preAD study group, Hovagim Bakardjian, Habib Benali, Hugo Bertin, Joel Bonheur LaurieBoukadida, Nadia Boukerrou, Enrica Cavedo, Patrizia Chiesa, Olivier Colliot, Marion Dubois, Geoffroy Gagliardi, Remy Genthon, Marie‐Odile Habert, Harald Hampel, Aurélie Kas, Foudil Lamari, Marcel Levy, Simone Lista, Christiane Metzinger, Fanny Mochel, Francis Nyasse, Catherine Poisson, Marie‐Claude Potier, Marie Revillon, Antonio Santos, Katia Santos Andrade, Marine Sole, Mohmed Surtee, Michel Thiebaud de Schotten, Andrea Vergallo, Nadjia Younsi
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Online Access:https://doi.org/10.1016/j.trci.2019.08.009
Tags: Add Tag
No Tags, Be the first to tag this record!